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Iron status markers in patients with small cell carcinoma of the lung.
Relation to survival
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Summary A longitudinal study of iron status markers (haemoglobin (Hb), serum (S-) iron, S-transferrin,
transferrin saturation, S-ferritin) was performed in 31 chemotherapy treated patients with small cell lung
cancer. At discovery, eight patients were anaemic (Hb < 121 g 1-). Hb, S-iron and transferrin saturation were
lower (P<0.01), and S-ferritin higher (P<0.01) than in healthy subjects. Chemotherapy induced an immed-
iate fall in Hb (P<0.003), increase in S-iron (P<0.003) and transferrin saturation (P<0.001). Later in the
disease a fall in S-transferrin (P<0.006) and an increase in S-ferritin (P<0.02) occurred. Thirty patients died
during the 2 years observation. S-ferritin at discovery was correlated to performance status score (r = 0.57,
P = 0.01) and to survival (r = - 0.63, P<0.0002). Patients with S-ferritin<4001g 1i (n = 13) had longer
survival than those with S-ferritin>400 fig 1- (n = 18) (P = 0.004).
Patients with untreated malignant disease demonstrate char-
acteristic changes in iron metabolism with anaemia, low
serum (S-) iron and S-transferrin together with inappropri-
ately elevated S-ferritin (Groop et al., 1978; Lee, 1983). In
general, the administration of cytotoxic agents induces a
further fall in haemoglobin (Hb), and an increase in S-iron
levels (Alfrey et al., 1966; Doll et al., 1983; Grau et al., 1985;
Pollera et al., 1987). The pathophysiological mechanisms of
these changes in iron kinetics are unclarified.
The aim of the present investigation was to study changes
in iron status markers in patients with small cell carcinoma
of the lung (SCCL), and to evaluate their relation to survival.
Material and methods
The material comprised 34 consecutive patients with SCCL;
two were excluded due to short survival <1 month, and one
due to porphyria cutanea tarda with iron overload. Median
age in the included 31 patients (24 males, seven females) was
64 years (range 39-76). Prior to treatment, bone marrow and
liver biopsies were performed to evaluate the stage of disease;
19 patients had limited disease, i.e. confined to one hemi-
thorax including bilateral supraclavicular lymph nodes.
Twelve patients had extensive disease, four of these had
bone marrow involvement. Performance status score (PS)
was assessed according to WHO criteria (WHO, 1979). All
patients received combination chemotherapy consisting of
lomustine, cyclophosphamide, methotrexate, vincristin, eto-
poside and doxorubicin in limited disease (0sterlind et al.,
1991), and of lomustine, cyclophosphamide, vincristin and
etoposide in extensive disease.
None took iron supplementation. Blood transfusions were
registered. Blood samples (non-fasting) were taken prior to
chemotherapy, and every 4th week until death. Hb was
measured on Coulter-S (1 g Hb 1-' = 0.062 mmol Hb l-),
S-iron by spectrophotometry (Iron Test RocheR on Kobas
BioR), S-transferrin by immunoelectrophoresis, and S-ferritin
by radioimmunoassay (Ferritin RIA AmershamR). Biochemi-
cal liver tests (S-aspartate aminotransferase and S-alkaline
phosphatase) were measured by standard methods. The con-
trol material consisted of 103 healthy 65-year-old subjects (55
males, 48 females) recruited through a population study in
Copenhagen County (Milman et al., GEN-MONICA study,
unpublished results). Iron status markers were measured by
the same methods as in the present study.
In the statistical analysis, Wilcoxon's rank sum test for
paired values was employed to evaluate the significance of
differences, and correlations were assessed with Pearson's
coefficient of correlation. Cumulative survival rates were cal-
culated by the Kaplan-Meier method and compared statistic-
ally by the log rank test.
Results
One male patient survived for more than 2 years. Median
survival in the other 30 patients was 337 days (range
86-576). Neither Hb nor iron status indicators displayed any
significant sex difference in the SCCL patients, and due to
the small number of females, values in both sexes were
pooled (Table I, Figures 1-2).
Haemoglobin
Eight patients (26%) had Hb values< 121 g1- (7.5 mmol
l-) at discovery, vs 12 (40%) at the last measurement before
death. There was a marked decline in Hb levels during the
disease, the major fall occurring 1 month after initiation of
chemotherapy (Table I, Figure 1).
Iron status markers
S-iron showed a significant increase from discovery to death.
The major increase was observed within 1 month after initia-
tion of chemotherapy. S-transferrin demonstrated a decline
occurring gradually and being significant from the third
month of survival. Transferrin saturation showed a significant
increase, being most pronounced in the first 3-4 months
after initiation of chemotherapy. None of the patients dis-
played values< 15%. High values> 60% were observed in 5
(17%) patients shortly before death. S-ferritin demonstrated
a significant rise, which occurred late in the disease, after
10-11 months of survival (Figure 2). The distributions of
S-ferritin values are shown in Table II. None of the patients
had values<20f.glh', and 16 (53%) had values >300;Lg I' at discovery compared to 29 (97%) at death.
Blood transfusions
The long term survivor received 42 transfusions, while 22
patients had a median of four transfusions (range 2-12).
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Table I Haemoglobin andiron statusmarkers(median and 5-95 percentile) inpatientswith SCCLandin
healthy subjects
Hb S-iron S-transferrin Transferrin S-ferritin
Patients (g1-') (Ismolt') (.molhV') saturation (%) (pg1')
134a Ila 28 21a 314a
Discovery (110-153) (4-20) (19-35) (11 -32) (51-1630)
(n = 31) <0.01 <0.05 <0.01 <0.01 <0.01
p Iiila 15b 21a 34 1128a
Death (93-129) (4-38) (15-32) (13-94) (337-2124)
(n = 30)
Healthy subjects S 148 19 30 30 s 150
(d= 55) (124-171) (11-30) (21-36) (17-50) (62-725)
(= 48) ? 140 ? 107
(116-158) (42-257)
Patients vs healthy subjects. ap<0.01; bp<0.05.
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Figure 1 Changes in serum iron, serum transferrin, transferrin
saturation and haemoglobin during course of disease in 31
patients with SCCL (mean ± s.e.m.).
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Figure 2 Changes in serum ferritin levels during course of
disease in 31 patients with SCCL (mean± s.e.m.).
There was no correlation between the number of transfusions
and iron status markers at death.
Biochemical liver tests
At discovery 16 (52%) patients had elevated S-transaminase
and/or S-alkaline phosphatase. Iron status markers in
patients with abnormal biochemical liver tests were not signi-
ficantly different from those in patients with normal liver
tests.
Stage ofdisease
There was no significant difference in iron status markers
between patients with limited and extensive disease.
Correlation between iron status markers
At discovery, correlations existed between S-ferritin vs S-
transferrin (r =-0.48, P<0.01), Hb vs S-iron (r= 0.58,
P<0.0005), and Hb vs S-transferrin (r = 0.42, P<0.02).
Survival
PS was correlated to survival (r =-0.37, P = 0.05). S-trans-
ferrin at discovery was correlated to survival (r = 0.44,
P<0.02), but closer analysis showed that this relation was of
no clinical relevance. S-ferritin at discovery showed a nega-
tive correlation to survival (log vs log values, r = - 0.63,
P<0.0002, Figure 3). Analysis of survival rates revealed that
a threshold ferritin value of 400 ytg 1' yielded the best
discrimination between the two survival groups (Figure 4).
Furthermore S-ferritin at discovery was correlated to PS
(r = 0.57, P = 0.01). Iron status markers at death showed no
correlation to survival.
Discussion
Iron status in patients with SCCL was profoundly influenced
by disease and chemotherapy. Prior to treatment, Hb values
were low and many patients were anaemic. Chemotherapy
was immediately followed by a decrease in Hb levels due to
inhibition of erythropoiesis (Alfrey et al., 1966); the addi-
Table H Distribution ofserum ferritinvalues inpatientswith SCCLat
discovery and prior to death
No. ofpatients
S-ferritin Discovery Death
(JAg1-') n = 31 n = 30
<=20 0 0
21-40 2 0
41-300 12 1
>300 17 29
n = 3131313128 27252221191814 9 7 7 3
0 6 0 1 2 3 4 5 6 7 8 9 10 11 1213 14 15
Time (months)
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Figure 3 Relation between survival and serum ferritin at dis-
covery in 31 patients with SCCL; regression line: y=-1.24 x
+ 5.56; r=-0.63, P<0.0002.
tional fall prior to death was probably caused by metastatic
marrow invasion.
Before chemotherapy, the patients were hyposideraemic,
consistent with the fact that malignant disease produce an
impaired release of iron from the storage compartments and
a fall in S-iron (Lee, 1983; Lipschitz et al., 1971). Chemo-
therapy induced a rise in S-iron levels, as described in other
investigations (Grau et al., 1985; Pollera et al., 1987). The
rise begins already 24-48 h after initiation of therapy
(Pollera et al., 1987). Throughout the remaining period of
disease, S-iron remained elevated. The reasons for these
changes in S-iron are unknown. Haemolysis can be excluded
according to previous studies (Doll et al., 1983; Pollera et al.,
1987), and increased iron absorption or decreased excretion
are unlikely to give these rapid fluctuations. A decreased Hb
synthesis per se induces a moderate rise in S-iron, as erythro-
poiesis modulates the release of iron from storage compart-
ments (Alfrey et al., 1966).
S-transferrin values at discovery were of the same order as
in healthy subjects, but declined after 3-4 months of disease.
Malignancies are known to reduce S-transferrin levels, prob-
ably due to decreased synthesis combined with increased
catabolism (Hughes et al., 1972; Lee, 1983).
The increase in transferrin saturation was a consequence of
the rise in S-iron, combined with an almost constant S-
transferrin level. None of the patients had values <15%,
indicating insufficient iron delivery to the erythron. Later in
the disease, there was a rise in saturation due to declining
S-transferrin and a further increase in S-iron.
In healthy subjects, the S-ferritin concentration reflects
mobilisable iron stores, mainly located in the liver, spleen
and bone marrow (Walters et al., 1973); values <20 tg I1
are indicative of 'exhausted', 21-40 gg-1' of 'small', 41-300
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Figure 4 Survival curves for patients with newly discovered
SCCL having serum ferritin >400 lg I' ( , n = 13), and
<400fig 1- I (-, n = 18) (P = 0.004).
lg 1-1 of 'normal' and >300jig 1' of 'increased' iron stores
(Milman et al., 1983).
To some extent S-ferritin behaves as an acute phase reac-
tant, being inappropriately elevated in infectious, inflamma-
tory and malignant diseases (Gropp et al., 1978; Lee, 1983).
S-ferritin was elevated at discovery and remained relatively
constant until late in the disease, where a marked rise was
observed at 10-11 months, probably reflecting an increased
tumour mass. The present ferritin assay uses antibodies
against basic spleen ferritin, and thus underestimates the
presence of acidic ferritin often produced in malignant
tumours (Hazard et al., 1977).
Prognostic indicators of survival are of importance to the
clinician in the decision for treatment. In a study comprising
778 patients with SCCL (0sterlind et al., 1986), a number of
clinical and biochemical variables (not including iron status
markers) were tested against survival. PS at the time of
diagnosis appeared to be the most weighty single factor. In
the present study, PS also correlated to survival. Further-
more, there was a pronounced correlation between S-ferritin
at discovery and survival, which was higher than the correla-
tion between PS and survival. A threshold S-ferritin value of
400tLg 1` divided the patients in groups with highly signifi-
cant differences in survival, i.e. high ferritin levels were
related to a short survival. Cox et al. (1986) also found a
relation between S-ferritin and survival in SCCL, using a
discriminative value of 600tig 1'. Whether S-ferritin may be
of clinical significance in the future evaluation of the prog-
nosis in patients with SCCL should be investigated in more
comprehensive studies.
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